Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

27.92 +0.42 (+1.53%)
Streaming Delayed Price Updated: 1:02 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday?
Wall Street kicked off the week on a cautious note, with major indexes trading relatively flat as investors seek more clarity on the economic and political landscape. 
Via Benzinga
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
These two stocks could be rivals in the intense GLP-1 space in the future. 
Via The Motley Fool
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout. 
Via The Motley Fool
What the Options Market Tells Us About Viking Therapeutics
Via Benzinga
Viking Therapeutics Unusual Options Activity For September 11
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $7,500 Today
Via Benzinga
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
Viking Therapeutics received an Overweight rating and a December 2025 price target of $80 from JPMorgan analysts. 
Via Benzinga
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market. 
Via MarketBeat
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns has a modest market cap of less than $800 million, and its possible upside could be massive. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond. 
Via The Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Terns Pharmaceuticals just proved that it's competitive in the weight loss field. 
Via The Motley Fool
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
The major indexes reclaimed key levels and many leaders flashed buy signals. 
Via Investor's Business Daily
These 2 Biotech Stocks Are Set to Soar
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. 
Via The Motley Fool
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track. 
Via The Motley Fool
Why Investors Plowed Into Viking Therapeutics Stock Today
The company is looking especially good after some bad news coming from a rival. 
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
An investment in these players today could score a big win down the road. 
Via The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug. 
Via The Motley Fool
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80. 
Via Benzinga
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
The company is working on a drug that targets GLP-1 and amylin to improve weight loss. 
Via Investor's Business Daily
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock. 
Via The Motley Fool
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected. 
Via Benzinga
Prediction: This Biotech Stock Will Outperform Nvidia in the Second Half of the Year
Nvidia is heading for a 118% gain this year. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
This business has solid results in hand, lots of cash, and more catalysts coming. 
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC. 
Via Benzinga
Why Viking Therapeutics Stock Got Thrashed on Tuesday
A monster rival is making aggressive moves in one particular segment. 
Via The Motley Fool
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.